UPDATE: AstraZeneca board rejects new offer from Pfizer
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Eli Lilly and Co. lost a United Kingdom lawsuit over its Alimta cancer treatment when a judge ruled Thursday that a generic version planned by Actavis Plc doesn’t breach European patents.
Officials with direct knowledge of the plan said participants in the first tier would receive limited coverage at no charge. A second tier would include dental and vision coverage and require participant contributions.
WellPoint Inc. competitor UnitedHealth Group Inc., the largest U.S. health insurer, will lead an industry effort to throw a spotlight on the prices paid for health-care services, making their costs available to consumers on the Internet.
Before the law took effect, experts warned that narrow networks could impact patient's access to care, especially in cheaper plans. But with insurance cards now in hand, consumers are finding their access limited across all price ranges.
Brazilian federal prosecutors had accused a Lilly subsidiary of incinerating toxic waste at the plant that it operated until 2003.
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
The American Medical Association says the exact number of doctors affected by tax fraud isn't known, but hundreds of cases have been confirmed, including dozens in Indiana.
When Tom Hanley couldn’t get large charitable foundations to support a wellness program he developed for central Indiana youth, he switched gears and adopted a fee-for-service model underwritten largely by sponsorships.
Top health insurance companies told members of Congress Wednesday that more than 80 percent of people who've signed up under the president's new health care law have gone on to pay their premiums.
Bayer AG’s $14.2 billion acquisition of Merck & Co. is the latest in a series of big pharma deals and it exposes a deepening split in the way drugmakers approach their portfolios.
Three large health insurers including Indianapolis-based WellPoint Inc. and Aetna Inc. say that a high percentage of their new Obamacare customers are paying their first premiums, partly undermining a Republican criticism of enrollment in the program.
The Indianapolis-based American Legion, the nation's largest veterans service group, called Monday for the resignations of U.S. Veterans Affairs Secretary Eric Shinseki and two of his top aides amid an investigation into allegations of corruption and unnecessary deaths.
Hospitals, which have forced orthopedic implant makers to lower their prices in recent years, may have a harder time doing so when the combined Zimmer-Biomet controls nearly 40 percent of the market.
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
Data from the U.S. Department of Health and Human Services show that a total of nearly 230,000 Indiana residents were eligible to enroll in a marketplace plan, but only about 132,000 had done so by the March 31 deadline.
The Accountable Care Consortium was envisioned as a vehicle through which the hospitals would eventually funnel all of their roughly $2.5 billion in annual contracts with health insurers and employers.
Before local hospitals slashed staff and expenses last year, they had been boosting the pay packages of their top executives faster than hospitals around the country. Seven of every 10 senior executives at the major hospital systems in Indianapolis saw their total compensation rise more than 10 percent from 2010 to 2012.
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.